Ally Bridge Group (PE) LLC

Thesis

Ally Bridge Group (ABG) is a global investment firm founded in 2013, focusing on life science innovation across private and public markets. Their mission is to generate superior risk-adjusted returns while addressing unmet medical needs through deep scientific, clinical research, M&A, and capital markets expertise. ABG specializes in mid-market and growth-oriented investments in life sciences, healthcare, and technology, with a global focus on the US and China. They employ complementary private equity (since 2013) and public equity (since 2018) strategies, investing across the capital structure and leveraging synergies between platforms. As of December 31, 2024, they managed approximately $1.35 billion in regulatory assets, with a prior report of $3.0 billion in AUM in September 2021. ABG typically leads or co-leads investments in companies aged 6-10 years, focusing on Biotechnology and Pharmaceuticals, with deal sizes ranging from $50 million to $100 million and average startup valuations between $500 million and $1 billion. The firm actively seeks new investments and operates as a growth equity firm with a strong emphasis on the healthcare sector.

Related lists

• Series C+ Healthcare investors
• Series C+ investors based in New York, NY